Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ERCC1 | P07992 | 4/20 | 0.53 |
| ▸ | ERCC4 | Q92889 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | GRK2 | P25098 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489513 | 0.89 | MEN1 (0.51) | PKMALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL14625078 | 0.85 | HDAC1 (0.61) | ALDH1A1LMNAKMT2ARAB9AMEN1 | |
| SCHEMBL19513461 | 0.82 | POLB (0.59) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL8621971 | 0.82 | ALDH1A1 (0.45) | ALDH1A1LMNAKMT2ARAB9AMEN1 | |
| SCHEMBL1623733 | 0.81 | ERCC1 (0.54) | PKMALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL1561387 | 0.81 | MAPT (0.70) | ALDH1A1LMNAKMT2ARAB9AMEN1 | |
| SCHEMBL6909543 | 0.80 | PKM (0.57) | PKMALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL4908547 | 0.80 | ERCC1 (0.54) | PKMALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL11674922 | 0.80 | ALDH1A1 (0.48) | ALDH1A1MAPTCA12CA1CA2 | |
| SCHEMBL19707555 | 0.80 | MEN1 (0.52) | ALDH1A1LMNAKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702000-A1 | ALKYLATION PROCESS | University of Liverpool (GB) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024224034-A1 | ALKYLATION PROCESS | THE UNIVERSITY OF LIVERPOOL (GB) | 2024-10-31 | — | — | WO | disclosed |
| EP-3079680-A2 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS | Angiogenex, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089495-A2 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS | ANGIOGENEX, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-8859538-B2 | Uses of substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2170350-B1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS INC (US) | 2013-09-11 | — | — | EP | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| EP-2170350-A2 | SUBSTITUTED IMIDAZOHETEROCYCLES | Cara Therapeutics, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-7592463-B2 | An imidazolidinone compounds is used in reaction as catalyst to lower the energy level of the lowest unoccupied molecular orbital | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2009-09-22 | — | — | US | disclosed |
| EP-0651739-B1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1997-04-09 | — | — | EP | disclosed |
| EP-0712838-A1 | ACYLPHENYLGLYCINE DERIVATIVE AND PREVENTIVE AND REMEDY FOR DISEASES CAUSED BY INCREASED COLLAGENASE ACTIVITY CONTAINING SAID COMPOUND AS ACTIVE INGREDIENT | KANEBO LTD. (JP) | 1996-05-22 | — | — | EP | disclosed |
| EP-0651739-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS. | BRITISH BIOTECH PHARM (GB) | 1995-05-10 | — | — | EP | disclosed |
| US-5378729-A | Diamide derivatives | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0592490-A4 | AMINO ACID DERIVATIVE ANTICONVULSANT | RES CORP TECHNOLOGIES INC (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0592490-A1 | AMINO ACID DERIVATIVE ANTICONVULSANT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-04-20 | — | — | EP | disclosed |
| WO-1994002447-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| WO-1992021648-A1 | AMINO ACID DERIVATIVE ANTICONVULSANT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-12-10 | — | — | WO | disclosed |
| EP-0263506-A2 | Anticonvulsant composition containing amino acid derivative and use of said amino acid derivative | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1988-04-13 | — | — | EP | disclosed |
| EP-0194464-A1 | Amino acid derivatives and use thereof for the preparation of an anticonvulsant | Research Corporation Technologies, Inc. (a Delaware corp.) (US) | 1986-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CNR2, CNR1, TRPV1 | PKM 4424/4885ALDH1A1 2355/4885LMNA 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.